# An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

> **NCT03137160** · PHASE2 · COMPLETED · sponsor: **Ohio State University** · enrollment: 4 (actual)

## Conditions studied

- Pyoderma Gangrenosum

## Interventions

- **BIOLOGICAL:** Ixekizumab

## Key facts

- **NCT ID:** NCT03137160
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-04
- **Primary completion:** 2018-08-16
- **Final completion:** 2018-08-16
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137160, "An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03137160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*